Overview

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Status:
Completed

Trial end date:
2020-12-23

Target enrollment:

Participant gender:

Summary

The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborators:

Intertek
Laboratory Corporation of America
Medidata Solutions
Pacific Biomarkers
Parexel
PPD
Quintiles, Inc.
Sysmex Inostics GmbH
Thermo Fisher Scientific
University of Colorado, Denver

Treatments:

Antibodies, Monoclonal
Cisplatin
Necitumumab
Pemetrexed